Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.

por Solomayer, E. F., Diel, I. J., Wallwiener, D., Bode, S., Meyberg, G., Sillem, M., Gollan, C., Kramer, M. D., Krainick, U., Bastert, G.
Publicado 1997

Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer

por Hohaus, S, Funk, L, Martin, S, Schlenk, R F, Abdallah, A, Hahn, U, Egerer, G, Goldschmidt, H, Schneeweiß, A, Fersis, N, Kaul, S, Wallwiener, D, Bastert, G, Haas, R
Publicado 1999

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF

por Colleoni, M, Litman, H J, Castiglione-Gertsch, M, Sauerbrei, W, Gelber, R D, Bonetti, M, Coates, A S, Schumacher, M, Bastert, G, Rudenstam, C-M, Schmoor, C, Lindtner, J, Collins, J, Thürlimann, B, Holmberg, S B, Crivellari, D, Beyerle, C, Neumann, R L A, Goldhirsch, A
Publicado 2002